Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,316 papers from all fields of science
Search
Sign In
Create Free Account
monoclonal antibody HeFi-1
Known as:
HeFi-1
, MOAB HeFi-1
A murine monoclonal antibody with potential antineoplastic activity. Monoclonal antibody HeFi-1 binds to CD30, a cell surface antigen found on…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
8 relations
B-Lymphocytes
Inhibition of Cell Proliferation
Metastasis Suppression
Reed-Sternberg Cells
Expand
Broader (1)
Monoclonal Antibodies
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
CD30 as Target for Radioimmunotherapy (RIT) of Lymphoma.
J. O. Staak
,
D. Colcher
,
S. Nagata
,
Jianyi Wang
,
I. Pastan
,
A. Raubitschek
2005
Corpus ID: 209230949
Objectives: CD30 is overexpressed on the cell surface by a variety of malignant diseases including Hodgkin’s lymphoma (HL). It is…
Expand
2004
2004
Increased Expression and Activation of CD30 Induce Apoptosis in Human Blood Eosinophils1
A. Berro
,
G. Perry
,
D. Agrawal
Journal of Immunology
2004
Corpus ID: 23365954
Eosinophils are one of the major effector cells in asthma, and controlling the number and survival of eosinophils might attenuate…
Expand
2003
2003
Proliferation of CD30+ T-helper 2 lymphoma cells can be inhibited by CD30 receptor cross-linking with recombinant CD30 ligand.
J. Willers
,
R. Dummer
,
W. Kempf
,
T. Kündig
,
G. Burg
,
M. Kadin
Clinical Cancer Research
2003
Corpus ID: 18652063
PURPOSE Cutaneous anaplastic large cell lymphomas (ALCLs) are characterized by the expression of CD30, spontaneous regression of…
Expand
2003
2003
Proliferation of CD 30 T-Helper 2 Lymphoma Cells Can Be Inhibited by CD 30 Receptor Cross-Linking with Recombinant CD 30 Ligand 1
J. Willers
,
R. Dummer
,
W. Kempf
,
T. Kündig
,
G. Burg
,
M. Kadin
2003
Corpus ID: 37033860
Purpose: Cutaneous anaplastic large cell lymphomas (ALCLs) are characterized by the expression of CD30, spontaneous regression of…
Expand
2000
2000
Characterization of the CD30L binding domain on the human CD30 molecule using anti-CD30 antibodies.
A. Franke
,
D. Jung
,
T. Ellis
Hybridoma
2000
Corpus ID: 31184258
CD30 and its counter-receptor CD30 ligand (CD30L) are members of the TNF-receptor/TNFalpha superfamily and function to regulate…
Expand
1989
1989
Characterization of Hodgkin's disease derived cell line HDLM-2.
H. Drexler
,
S. Gignac
,
+4 authors
J. Minowada
Recent results in cancer research. Fortschritte…
1989
Corpus ID: 21010432
The cell line HDLM-2 was established from the pleural effusion of a patient with Hodgkin's disease. Here, we describe the…
Expand
1987
1987
Effect of monoclonal antibodies anti-2H9, anti-IRac, and anti-HeFi-1 on the surface antigens of Reed-Sternberg cells.
S. Hsu
,
Y. Ho
,
P. Hsu
Journal of the National Cancer Institute
1987
Corpus ID: 6712622
The interaction of 3 monoclonal antibodies (MAbs)--anti-HeFi-1, anti-2H9, and anti-IRac--with Reed-Sternberg (RS) cells was…
Expand
1987
1987
The H-RS-like cells in infectious mononucleosis are transformed interdigitating reticulum cells.
S. Hsu
,
X. Zhao
American Journal of Pathology
1987
Corpus ID: 10863087
The lymphoid tissues from patients with infectious mononucleosis or, less frequently, with other reactive conditions may contain…
Expand
1986
1986
Monoclonal antibodies against SU-DHL-1 cells stain the neoplastic cells in true histiocytic lymphoma, malignant histiocytosis, and Hodgkin's disease.
S. Hsu
,
M. Pescovitz
,
P. Hsu
Blood
1986
Corpus ID: 1120188
Three murine monoclonal antibodies, named 2H9, 1E9 and 1A2, were produced after immunization of BALB/c mice with cells of the SU…
Expand
1986
1986
Phenotypes and phorbol ester-induced differentiation of human histiocytic lymphoma cell lines (U-937 and SU-DHL-1) and Reed-Sternberg cells.
S. Hsu
,
P. Hsu
American Journal of Pathology
1986
Corpus ID: 22527829
Hodgkin's mononuclear cells, Reed-Sternberg (H-RS) cells, and U-937 and SU-DHL-1 histocytic cell lines were induced to…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE